icon-avatar
Economía

COMUNICADO: La EMA acepta la solicitud de ampliación de indicación para el uso de Zonegran® (zonisamida) de Eisai (y 2)

    EISAI
    5.210,00+0,39%

    [1] Rosati A, Pellacani P, Falchi M, Guerrini R. Preliminary results from the CATZ Study: a phase III, double-blind, randomised, placebo-controlled trial to assess the efficacy and safety of adjunctive zonisamide in paediatric patients with partial-onset seizures. P870 Abstract#914 Presented at 29th International Epilepsy Congress, 28th August until 1st September, 2011, Rome [2] Eisai Ltd. (2005). Zonegran Summary of Product Characteristics [http://emc.medicines.org.uk/] [3] Pugliatti M et al. Estimating the cost of epilepsy in Europe: A review with economic modeling. Epilepsia 2007: 48(12) 2224 - 2233 [4] ILAE/IBE/WHO, Epilepsy in the WHO European Region: Fostering Epilepsy Care in Europe 2010. Available from; http://www.ilae-epilepsy.org/Visitors/Documents/EUROReport160510.pdf [http://www.ilae-epilepsy.org/Visitors/Documents/EUROReport160510.pdf] (Accessed June 2011) [5] Epilepsy Society UK: http://www.epilepsysociety.org.uk/AboutEpilepsy/Whatisepilepsy/Epilepsy-didyouknow [http://www.epilepsysociety.org.uk/AboutEpilepsy/Whatisepilepsy/Epilepsy-didyouknow] (Accessed June 2011) [6] Forsgren L. Epilepsy in Children. 2nd Ed London. Arnold, 2004. 21-25

    CONTACTO: CONTACTO: Cressida Robson, +44(0)7908-314-155,Cressida_Robson@eisai.net, de Eisai Europe Ltd; o Benjamyn Tan,+44(0)207-798-9262, benjamyn.tan@toniclc.com, o Leah Peyton,+44(0)7792-034-191, leah.peyton@toniclc.com, ambos de Tonic LifeCommunications

    Sitio Web: http://www.EISAI (JP4523.TK)com/

    Relacionados

    WhatsAppFacebookFacebookTwitterTwitterLinkedinLinkedinBeloudBeloudBluesky